Interview with Ulrich Eggert, Managing Director, Astellas Pharma Germany
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Address: D-80971 München,Germany
Tel: 49 089 / 4544-01
Astellas Pharma has its German headquarters in Munich and employs approximately 400 employees in clinical development, marketing and distribution. Astellas Pharma achieved a turnover of around 200 million euros in the German pharmacy market mainly with drugs for the treatment of transplant medicine, urology, Pneumology, Dermatology and self.Worldwide Astellas is ranked 23 in the pharmaceutical ranking. The accumulated consolidated revenues in fiscal year 2007 was at 6.1 billion euros. Astellas employed around 14 000 employees worldwide.
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, critiques the draft EU Pharma Regulation…
Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such…
Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. (LSAA), which lobbies on behalf of European venture capitalists in the life sciences space, launches a critique of current pharmaceutical…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19…
The Contract Development and Manufacturing Organization (CDMO) sector has flousished in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain…
At the recent World Economic Forum in Davos, Chair of the Executive Board and CEO of Merck, Belén Garijo, speaking in a session on workforce transformation in the digital era,…
In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the…
The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with…
A roundup of some of the biggest recent stories from German pharma, including the latest on beleaguered Bayer CEO Werner Baumann, Merck KGaA’s latest investments in France and Germany, and…
A snapshot of Germany, one of the European pharma hotspots featured in PharmaBoardroom’s latest report, InFigures: European Pharma Hotspots 2022. With the largest market value in Europe, Germany remains at…
See our Cookie Privacy Policy Here
